Skip to main content
OpenTrials

Clinical trial condition

Restless Legs Syndrome

Explore clinical trials studying Restless Legs Syndrome. Study availability and eligibility vary by location and protocol.

148 public trials 9 recruiting studies
Refine in advanced search Browse all conditions

Restless Legs Syndrome trial results

Completed

Safety and Effect of Mirapex(Pramipexole) Tablet Among Korean RLS

NCT01170091

Conditions
Dyssomnias, Mental Disorders, Nervous System Diseases, +4 more
Locations
  • Boehringer Ingelheim Investigational Site 1 Busan, South Korea
  • Boehringer Ingelheim Investigational Site 2 Busan, South Korea
  • Boehringer Ingelheim Investigational Site 3 Busan, South Korea
  • Boehringer Ingelheim Investigational Site 32 Daegu, South Korea
View all 36 locations
View Trial Details
Completed

A Study in Patients Suffering From Idiopathic Restless Legs Syndrome Who Responded to a Preceding, 6-month Treatment With Open-label Pramipexole Including Titration (0.125, 0.25, 0.5, 0.75 mg Orally q.n.)

NCT00152958

Conditions
Dyssomnias, Mental Disorders, Nervous System Diseases, +4 more
Locations
  • Boehringer Ingelheim Investigational Site Berlin, Germany
  • Charité Campus Virchow-Klinikum Berlin, Germany
  • emovis GmbH Berlin, Germany
  • Boehringer Ingelheim Investigational Site Chemnitz, Germany
View Trial Details
Completed

Efficacy and Safety of Pramipexole Compared to Placebo in the Treatment of Restless Legs Syndrome (RLS)

NCT00133198

Conditions
Dyssomnias, Mental Disorders, Nervous System Diseases, +4 more
Locations
  • Pivotal Research Centers Peoria, Arizona, United States
  • Mayo Clinic - Scottsdale Scottsdale, Arizona, United States
  • Boehringer Ingelheim Investigational Site Fountain Valley, California, United States
  • HealthQuest Clinical Trials Research San Diego, California, United States
View all 44 locations
View Trial Details
Completed

Assess Efficacy and Safety of the Dopamine Agonist Pramipexole Versus Levodopa / Benserazide (Madopar® DR) in Patients With Restless Legs Syndrome

NCT00144209

Conditions
Dyssomnias, Mental Disorders, Nervous System Diseases, +4 more
Locations
  • Boehringer Ingelheim Investigational Site Bad Zurzach, Switzerland
  • Boehringer Ingelheim Investigational Site Basel, Switzerland
  • Boehringer Ingelheim Investigational Site Basel, Switzerland
  • Boehringer Ingelheim Investigational Site Bern, Switzerland
View Trial Details
Completed

Non-interventional Observational Study of Pramipexole in Restless Legs Syndrome: Impact on Quality of Life

NCT00539461

Conditions
Dyssomnias, Mental Disorders, Nervous System Diseases, +4 more
Locations
  • Boehringer Ingelheim Investigational Site Aalen, Germany
  • Boehringer Ingelheim Investigational Site Aarbergen, Germany
  • Boehringer Ingelheim Investigational Site Adendorf, Germany
  • Boehringer Ingelheim Investigational Site Aham, Germany
View all 317 locations
View Trial Details
Completed

Efficacy and Safety of Pramipexole (PPX) in Moderate to Severe Idiopathic Restless Legs Syndrome (RLS) Patients

NCT00275457

Conditions
Dyssomnias, Mental Disorders, Nervous System Diseases, +4 more
Locations
  • Univ.-Klinik für Neurologie Graz, Austria
  • Univ.-Klinik für Neurologie Innsbruck, Austria
  • AKH der Stadt Linz Linz, Austria
  • Confraternität Privatklinik Vienna, Austria
View all 34 locations
View Trial Details
Completed

Pramipexole (BI-Sifrol®) Orally Once Daily for 6 Weeks in Patients With Primary Restless Legs Syndrome

NCT00152997

Conditions
Dyssomnias, Mental Disorders, Nervous System Diseases, +4 more
Locations
  • Boehringer Ingelheim Investigational Site Akita, Akita, Japan
  • Boehringer Ingelheim Investigational Site Kochi, Kochi, Japan
  • Boehringer Ingelheim Investigational Site Kurume, Fukuoka, Japan
  • Boehringer Ingelheim Investigational Site Otaru,Hokkaido, Japan
View Trial Details
Completed

A 6 Week Trial to Study the Efficacy and Safety of a Starting Dose 0.25 mg Pramipexole (Mirapex) in Patients With RLS

NCT00375284

Conditions
Dyssomnias, Mental Disorders, Nervous System Diseases, +4 more
Locations
  • 248.616.065 Boehringer Ingelheim Investigational Site Birmingham, Alabama, United States
  • 248.616.028 Boehringer Ingelheim Investigational Site Dothan, Alabama, United States
  • 248.616.035 Boehringer Ingelheim Investigational Site Mesa, Arizona, United States
  • 248.616.025 Boehringer Ingelheim Investigational Site Peoria, Arizona, United States
View all 52 locations
View Trial Details

Related conditions